Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

Autor: Spectrum Pharmaceuticals, Inc.
Zdroj: Business Wire (English). 02/08/2023.
Abstrakt: Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje